ADMA Biologics Return On Equity vs. Return On Asset

ADMA Stock  USD 21.30  0.07  0.33%   
Based on ADMA Biologics' profitability indicators, ADMA Biologics' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess ADMA Biologics' ability to earn profits and add value for shareholders.
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
(0.21)
Current Value
(0.20)
Quarterly Volatility
5.80170243
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, ADMA Biologics' Days Sales Outstanding is projected to increase significantly based on the last few years of reporting. The current year's Operating Cash Flow Sales Ratio is expected to grow to 0.04, whereas Price To Sales Ratio is forecasted to decline to 3.72. At present, ADMA Biologics' Operating Income is projected to decrease significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 1.1 M, whereas Income Before Tax is forecasted to decline to (29.7 M).
For ADMA Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ADMA Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ADMA Biologics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ADMA Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ADMA Biologics over time as well as its relative position and ranking within its peers.
  

ADMA Biologics' Revenue Breakdown by Earning Segment

Check out Trending Equities.
For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
14
Earnings Share
0.28
Revenue Per Share
1.661
Quarterly Revenue Growth
0.781
Return On Assets
0.1989
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

ADMA Biologics Return On Asset vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining ADMA Biologics's current stock value. Our valuation model uses many indicators to compare ADMA Biologics value to that of its competitors to determine the firm's financial worth.
ADMA Biologics is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about  0.56  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for ADMA Biologics is roughly  1.79 . At present, ADMA Biologics' Return On Equity is projected to slightly grow based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ADMA Biologics' earnings, one of the primary drivers of an investment's value.

ADMA Biologics' Earnings Breakdown by Geography

ADMA Return On Asset vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

ADMA Biologics

Return On Equity

 = 

Net Income

Total Equity

 = 
0.36
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

ADMA Biologics

Return On Asset

 = 

Net Income

Total Assets

 = 
0.2
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

ADMA Return On Asset Comparison

ADMA Biologics is currently under evaluation in return on asset category among its peers.

ADMA Biologics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in ADMA Biologics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ADMA Biologics will eventually generate negative long term returns. The profitability progress is the general direction of ADMA Biologics' change in net profit over the period of time. It can combine multiple indicators of ADMA Biologics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income21.6 M22.7 M
Income Before Tax-28.2 M-29.7 M
Net Loss-28.2 M-29.7 M
Total Other Income Expense Net-49.9 M-47.4 M
Income Tax Expense8.2 M5.9 M
Net Loss-22.8 M-24 M
Non Operating Income Net Other-6.5 M-6.2 M
Net Loss-59.3 M-62.3 M
Interest IncomeM1.1 M
Net Interest Income-23.5 M-22.4 M
Change To Netincome17.6 M18.5 M
Net Loss(0.13)(0.13)
Income Quality(0.31)(0.30)
Net Income Per E B T 1.16  0.90 

ADMA Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on ADMA Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ADMA Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ADMA Biologics' important profitability drivers and their relationship over time.

Use ADMA Biologics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ADMA Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ADMA Biologics will appreciate offsetting losses from the drop in the long position's value.

ADMA Biologics Pair Trading

ADMA Biologics Pair Trading Analysis

The ability to find closely correlated positions to ADMA Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ADMA Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ADMA Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ADMA Biologics to buy it.
The correlation of ADMA Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ADMA Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ADMA Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ADMA Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your ADMA Biologics position

In addition to having ADMA Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Commodities Funds Thematic Idea Now

Commodities Funds
Commodities Funds Theme
Funds or Etfs investing in commodities such as oil, gold, corn, soy, and agricultural goods. The Commodities Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Commodities Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:
Check out Trending Equities.
For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
To fully project ADMA Biologics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ADMA Biologics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ADMA Biologics' income statement, its balance sheet, and the statement of cash flows.
Potential ADMA Biologics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although ADMA Biologics investors may work on each financial statement separately, they are all related. The changes in ADMA Biologics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ADMA Biologics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.